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Summary Tissue inhibitor of metalloproteinase (TIMP) has been reported to inhibit tumour invasion through an inactivation of matrix
metalloproteinase (MMP) both in vitro and in vivo. Among the TIMP family, TIMP-1 possesses not only proteinase inhibitory activity but also
a growth-promoting function. However, the significance of the expression of TIMP-1 in human gastric carcinoma tissue has yet to be clarified.
In 50 examined cases of gastric carcinoma, 44 (88%) cases showed a higher expression of TIMP-1 mRNA in the biopsy samples from the
tumour tissue (T) than in the biopsy samples from the corresponding normal tissue (N), as determined by semiquantitative reverse
transcriptase-polymerase chain reaction (RT-PCR). In a multivariate analysis, the T/N ratio of TIMP-1 mRNA was found to be an independent
factor influencing the depth oftumour invasion and was the second most important factor in determining the prognosis of patients. As RT-PCR
assay can be performed on biopsy specimens obtained before surgery, an evaluation of the TIMP-1 expression in biopsy specimens by RT-
PCR may thus provide useful preoperative information on tumour aggressiveness.
Keywords: tissue inhibitor of metalloproteinase 1; gastric carcinoma; biopsy specimen; reverse transcriptase-polymerase chain reaction;
multivariate analysis
Tumour cells have to degrade the components of the extracellular
matrix (ECM) to invade the surrounding tissue and the vascular or
lymphatic vessels to form metastatic colonies at distant sites. The
matrix degradation in the basement membrane during the
metastatic process is, more or less, closely related to activities of
various subtypes of matrix metalloproteinase (MMP) and the
corresponding tissue inhibitor of matrix metalloproteinase
(TIMP). In general, MMPs facilitate the invasion of the tumour;
on the other hand, TIMPs also play an important role in inhibiting
MMPs. The TIMP-1 transfected cells or carcinoma cells with an
abundant expression ofTIMP-1 mRNA inhibit the MMPs' activity
to invade the model of basement membranes in various human
carcinoma cell lines (Sato et al, 1992; Azuma et al, 1993; Tsuchiya
et al, 1993; Belloc et al, 1995; Miyagi et al, 1995).
Recent studies have reported an alternative function of TIMP-1,
i.e. as agrowth factor; it is highlyhomologous with erythroid poten-
tiating activity (EPA), which is an autocrine growth factor for the
erythroid leukaemia cell line K562 (Docherty et al, 1985; Avalos et
al, 1988). Moreover, TIMP-1 also shares homology with afibroblast
elongation factor that is secreted from colon carcinoma cells and
which stimulates tumour cell proliferation (Agrez et al, 1995). The
TIMP-1 RNA levels were higher in primary colorectal carcinomas
with distant metastasis than in those without metastasis (Zeng et al,
1995), and the expression of TIMPs increased with the advance of
the neoplastic process (Urbanski etal, 1993). With respect to gastric
carcinoma, the enhanced TIMP-1 production in carcinoma
tissues was also reported by Nomura et al (1996). Therefore, it is
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considered important to determine whether or not TIMP-1 may
possess a function that accelerates malignant potentiality.
In the present study, we studied the expression of TIMP-1
mRNA in human gastric carcinoma tissue by an RT-PCR assay
that enabled us to analyse small sample amounts, such as biopsy
specimens, before surgery (Hirokoshi et al, 1992). We examined
the correlation between its expression and clinicopathological
variables, as well as the significance of its expression as an inde-
pendent factor to predict the depth of tumour invasion and patient
prognosis. We would thus like to emphasize that TIMP-1 expres-
sion may be one of the factors indicating the aggressiveness of
gastric carcinomas.
MATERIALS AND METHODS
Biopsy specimens
Biopsy specimens from 50 patients, including 30 men and 20
women, with gastric carcinoma were available for this study. The
average age was 67.5 years with a range from 38 to 87 years. We
obtained three and four biopsy specimens from the tumour and
normal tissue respectively. Two specimens from tumour tissue and
two specimens from normal tissue were used for RNA extraction.
The other specimens from the tumour and normal tissue were used
for the pathological diagnosis. For tumour biopsy samples, we
obtained the tissue from the edge of the primary tumour because
the edge area contains both tumour and stromal tissues in the spec-
imen. Consequently, we checked and confirmed that all biopsy
specimens stained with haematoxylin and eosin contained tumour
epithelial tissue and stromal tissue in the tumour biopsy specimen,
and normal epithelial tissue and stromal tissue in the normal
biopsy specimen. In most ofthe above cases, normal biopsy spec-
imens, i.e. specimens obtained from the non-cancerous mucosal
tissue, disclosed chronic gastritis with mild to severe stromal
fibrosis and inflammatory cell infiltration.
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Figure 1 (A) Autoradiograms show amplicons of tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) produced by reverse transcriptase - polymerase chain
reaction (RT-PCR) on serial amounts of RNA from a gastric carcinoma cell line, MKN-7. The linear range of amplification was observed in 1.0 gg of RNA. (B)
The relationship between the cycle number of PCR and the radioactivity of the amplified product of TIMP-1. The suitable cycle number was 24
Resected specimens
To examine the discrepancy ofthe results between biopsy samples
and resected samples, we compared both results in ten cases. In
this case, the resected specimens were those obtained from the
central cut slice ofthe primary tumour and the normal tissue in the
surgically resected stomach.
Gastric carcinoma cell line for the preliminary
experiment
MKN-7, a representative gastric carcinoma cell line, was studied
in the preliminary experiments to quantify the amplified PCR
product. This cell line was maintained in Dulbecco's modified
Eagle medium containing 10% fetal calf serum and antibiotics.
RNA preparation from tissue specimens
The samples for RNA extraction were immediately stored at
-80°C until use. The total RNA was then extracted according to
the method of acid guanidinium thiocyanate - phenol - chloro-
form extraction (Chomczynski and Sacchi, 1987). All samples
were treated in Eppendorf tubes (Eppendorf, Germany) and were
handled with gloves to avoid contamination with RNAase.
Reverse transcription
The total RNA of both the tumour and the normal samples from
the 50 cases was then reverse transcribed using random hexamer
primers into the cDNA as described previously (Mori et al, 1995).
Oligonucleotide primers of TIMP-1
On the GenBank accession no. S68252, both the sense and anti-
sense primers were synthesized using by an Applied Biosynthesis
394 PCR-Mate DNA Synthesizer. The primer sequences ofTIMP- 1
were as follows: sense primer (5'-GCCCCTGGCTTCTG-
GCATCCT-3') corresponding to human TIMP cDNA 18 to 38
(GenBank) and antisense (5'-GAGGCAGGCAGGCAAGGTGAC-
3') corresponding to human TIMP cDNA 557 to 577 (GenBank).
These primers amplified the 559-bp fragment ofTIMP-1 cDNA.
The semiquantitative detection of mRNA
In order to evaluate the amplified product quantitatively by PCR,
preliminary experiments were carried out to determine the suitable
number of cycles using the linear range of the PCR product in
cDNA from MKN-7, a representative gastric carcinoma cell line
(Figure 1) (Wang et al, 1989). As a result, the most suitable
number of PCR cycles for TIMP- 1 was determined to be 24. The
acceptable amount ofRNA to be reverse transcribed for the ampli-
fication ranged from 0.01 to 10 ,ug because ofthe linear correlation
between the amplified products and the amount of RNA. cDNA
corresponding to 1.0 ,ug of RNA was thus found to be suitable to
perform the PCR.
Polymerase chain reaction
The amplification of TIMP-1 cDNA was performed in a total
volume of 25 il, which included lOx PCR buffer (100 mM Tris-
HCI, pH 8.3, 500 mm potassium chloride, 15 mM magnasium
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Figure 2 The samples obtained from three patients were independently
assayed two times, starting each time with a new 1-,g sample of RNA.
Consequently, the first and the second results were almost similar in each
case and showed good reproducibility
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Figure 3 Relationship between the T/N ratio of TIMP-1 expression in the
resected specimens and in the biopsy specimens from ten representative
cases of gastric carcinoma. There was a significant correlation between them
(P = 0.0157, r = 0.734)
chloride, 1% Triton X-100), 25 mM dNTP (mixed dATP, dCTP,
dGTP and dTTP; each 100 mm), 15 mm TIMP-1 each primer and 1
unit of Taq DNA polymerase (Promega, Madison, WI, USA). The
antisense primer was end labelled with [y-32P]ATP by using T4
polynucleotide kinase (Takara, Japan). The reactions were
subjected to 24 cycles for 1 min at 940C, 1 min at 600C and 1 min
and 30 s at 72°C. The amplified DNA fragment was elec-
trophoresed on 1.5% agarose gel containing ethidium bromide
with a DNA molecular weight marker for comparison. Next, the
radioactivities of the amplified products were analysed using a
Fuji Image Analyzer (BAS1000, Fuji Photo Film).
Reproducibility of the experiments
An experiment indicating the reproducibility of the quantification
was performed. The samples obtained from three patients were
independently assayed two times, starting each time with a new
1-jg sample of RNA.
TIMP-1
T/N ratio
559 bp
9.1 9.6 0.2 14.0
Figure 4 Representative cases of the expression of amplified TIMP-1 in both
tumours and normal specimens from patients with gastric carcinoma. The
numbers described below indicate the tumour
- normal (T/N) ratio of TIMP-1
expression
Statistical analysis
The association between the clinicopathological variables and the
T/N ratio of the TIMP-1 was analysed using Student's t-test and
Fisher's exact test. In addition, a logistic analysis was also
performed to ascertain the independence ofthe TIMP- 1 expression
for determining the patient prognosis.
RESULTS
Reproducibility of RT-PCR analysis
The first and the second results were almost the same in each case
and showed a good reproducibility (Figure 2).
Comparison of the data from the resected specimens
and the biopsy specimens
The T/N ratio ofTIMP- 1 expression in the resected specimens was
3.84, while that in the biopsy specimens was 3.55. There was a
good correlation between the two as shown in Figure 3 (r = 0.734,
P = 0.016). These findings suggest that the results of the biopsy
specimens reflect those ofthe resected specimens.
Analysing the TIMP-1 mRNA levels in tumour and
normal tissues
The expression of TIMP-1 mRNA in all 50 cases with gastric
carcinoma was observed in both the tumour and the normal
samples (Figure 4). The expression of TIMP-1 mRNA could be
detected in all biopsy specimens obtained from the normal tissue,
and its level varied in each case. We thus considered it to be appro-
priate to compare the expression level in tumour samples with that
in normal samples in each case. The expression level of TIMP-1
was evaluated using the tumour-normal (T/N) ratio of TIMP-1.
The average T/N ratio was 7.21, with a range of 85.4 to 0.68.
Forty-four cases showed a higher TIMP-1 expression in the
tumour specimens than in the normal specimens. Table 1 shows
the relationship between the T/N ratio of TIMP-1 mRNA expres-
sion and its clinicopathological features using Student's t-test.
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Table 1 Clinicopathological variables of the patients studied and the
tumour-normal ratio of the tissue inhibitor of metalloproteinase-1 mRNA in
gastric carcinomas
Variables n TIMP-1 mRNA P-value
T/N ratioa
Sex NSb
M 30 6.9±2.4
F 20 7.7 ± 4.2
Histology NS
Intestinal type 29 7.4 ± 2.9
Diffuse type 21 7.0 ± 3.5
Depth of tumour invasion NS (0.077)
Within muscularis propria 29 3.9 ± 0.6
Beyond subserosa 21 11.8± 5.0
Lymph vessel invasion NS
Present 33 8.8± 3.3
Absent 17 4.2 ± 0.8
Vascular vessel invasion NS
Present 12 10.2 ± 6.0
Absent 38 6.3 ± 2.2
Lymph node metastasis NS
Present 30 9.8 ± 3.6
Absent 20 3.3 ± 0.5
Stage 0.042
landll 30 3.6±0.6
lIl and IV 20 12.6±5.2
Prognosis 0.007
Cancer death 12 17.7 ± 8.5
Alive 36 4.0± 0.5
Other 2 2.3 ± 0.2
aMean ± standard deviation. bNS, no significant difference.
Twenty patients belonging to stage III orIV showed a significantly
higher T/N ratio ofTIMP-1 mRNA than the 30 patients belonging
to stage I or II (P = 0.042). A significant difference was also
observed between the T/N ratio in the 12 patients who died of
primary cancer and that of the 36 patients who were still alive at
the time of writing (P = 0.007). With respect to the depth of
tumour invasion, the cases of tumours invading the subserosa or
deeper showed a higher T/N ratio than those invading up to the
muscularis propria, but it did not reach a statistically significant
difference (P = 0.077). No significant differences were found
between any other clinicopathological features.
The logistic analysis is shown in Table 2. TIMP-1 was the third,
and independent, determinant factor for the depth oftumour inva-
sion (r = 1.748, P = 0.038) (Table 2A). Although TIMP-1 was not
an independent prognostic factor (r = 0.080, P = 0.07), it was the
second major prognostic factor after the depth oftumour invasion
(Table 2B).
DISCUSSION
Three TIMP genes (TIMP-1, TIMP-2 and TIMP-3) have so far
been identified (Murphy et al, 1981; Stettler-Stevenson et al,
1989; Palvoff et al, 1992). TIMP-1 possesses 41% amino acid
homology with TIMP-2. TIMP-1 is a Mr 28 000 glycoprotein and
binds to MMPs in a 1:1 molar ratio and specifically inhibits MMP
activities (Welgus et al, 1981). TIMP-1 forms a complex with
proMMP9 and inhibits the activation ofproMMP9 by stromelysin
(Goldberg et al, 1992); inhibition of activity is the result of
binding the active site ofthe MMP (Birkedal-Hansen et al, 1993;
Denhardt et al, 1993).
During the invasion and metastatic progression of the carci-
noma cells, TIMPs have been reported to be a negative regulator
ofMMPs in human and mouse tumour models in vitro and in vivo.
The TIMP-l antisense transfected Swiss 3T3 cell lines reduced the
invasive activity with a lowerexpression ofTIMP-1 (Khokha et al,
1989). TIMP-1 gene transfected gastric carcinoma cells have been
reported to reduce the ability of invasion or metastasis (Tsuchiya
et al, 1993). Several previous studies have revealed that highly
malignant tumours produce both higher MMPs and lower TIMPs,
while less malignant tumours successfully inhibit the activities of
MMPs by TIMP activity (Sato et al, 1992; Azuma et al, 1993;
Miyagi et al, 1995; Mohanam et al, 1995).
However, in another study using clinical samples, the expres-
sion ofTIMP mRNA was higher in carcinoma tissue. In studies of
various carcinoma cases, such as stomach, colorectal, head and
neck, and pancreas, both MMPs and TIMPs were found to corre-
late with an increased metastatic and invasive potential of tumour
cells (Polette et al, 1993; Urbanski et al, 1993; Gress et al, 1995;
Zeng et al, 1995; Nomura et al, 1996). Zeng et al (1995) reported
that higher TIMP-1 RNA levels were found in colorectal carci-
noma with metastasis than in those without metastasis. Urbanski et
al (1993) reported that the expression ofTIMP mRNA thus paral-
leled the expression of MMPs and was also highly intercorrelated
with the neoplastic process of human sporadic colorectal carci-
nomas. We demonstrated in this gastric carcinoma study that the
expression ofTIMP-1 RNA was an independent factorinfluencing
Table 2
Variables Regression coefficient Standard error Odds ratio (95%confidence interval) P-value
(A) Multivariate analysis on the determination ofthe
depth oftumourinvasion (logistic analysis)
Lymphatic vessel invasion 2.897 1.20 18.1 (1.63-201) 0.002
Vascular vessel invasion 1.803 0.93 6.07 (0.934-39.4) 0.035
TIMP-1 1.748 0.911 5.74 (0.918-35.9) 0.038
(B) Multivariate analysis on the determination ofthe
patientprognosisa (logistic analysis)
Depth of tumour invasion 2.45 0.884 11.6 (1.95-68.8) 0.002
TIMP-1 0.08 0.09 1.08 (0.903-1.30) 0.07
aTwo patients who died during the operation were excluded from the analysis.
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the depth oftumour invasion and the second determinant factor for
patient prognosis after the depth of tumour invasion.
A discrepancy still exists however between the function of
TIMP-1 as an inhibitor of tumour cell invasion in vitro and the
higher expression ofTIMP-1 in human carcinoma cells, according
to previous reports or our findings. There are several possible
explanations for this discrepancy. First of all, a higher expression
of MMPs was observed in tissues with invasive carcinoma cells,
which induce macrophages with cytokines and thus elevate the
expression of TIMPs (Campbell et al, 1991; Lotz and Guerne,
1991; Partridge et al, 1993; Richards and Agro, 1994). Second, as
suggested by several investigators, TIMP-1 has two distinct activi-
ties, i.e. a metalloproteinase inhibitory activity and a growth factor
activity (Avalos et al, 1988; Agrez et al, 1995; Chesler et al, 1995).
Recent advances in the techniques of molecular biology have
enabled clinicians to obtain both more detailed and more objective
information on tumour biology. Such advances include the
clarification of multiple-step carcinogenesis in gastrointestinal
carcinomas; molecular-level diagnoses, such as the detection of
micrometastasis in lymph nodes (Mori et al, 1995), bone marrow
or peripheral blood samples (Mori et al, 1996); or molecular-level
new therapies, such as gene therapy. A new, molecular-level prog-
nostic factor still needs to be established that can be widely used in
the practical follow-up of patients (Mori et al, 1993a and b). RT-
PCR assays enable the molecular biological analysis of small
samples. Some problems exist, however, when performing such
analyses on small biopsy samples. The first is the problem of
reproducibility. In this study, we confirmed that RT-PCR for the
TIMP-1 gene showed almost the same results when the experi-
ments were repeated. The second problem is whether or not the
biopsy specimens accurately reflect the whole material of the
resected specimens. We compared the RT-PCR results obtained
from biopsy specimens with those from resected specimens. The
results consequently demonstrated a significantly good correla-
tion. We thus consider that, at least for the TIMP-1 gene, the
results obtained from the biopsy specimens accurately reflect those
obtained from resected specimens of the primary tumour, and we
believe that useful preoperative information on molecular-level
factors can be achieved by the molecular examination of biopsy
specimens.
The present study demonstrated that the evaluation of TIMP-1
expression using an RT-PCR assay with biopsy specimens may
therefore be useful in predicting the aggressive behaviour of
gastric carcinomas. Such an assay is objective and can be done
preoperatively, and therefore it is considered to be useful in a
clinical setting.
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